3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Genitourinary
1
Conditions
Mesothelioma, Malignant
7
Ovarian Neoplasms
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solitary Fibrous Tumor, Pleural
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Penile Neoplasms
1
Pelvic Neoplasms
1
Metastatic Solid Tumors
1
Mesothelioma
1
Lung Neoplasms
1
Liposarcoma
1
Fallopian Tube Neoplasms
1
Desmoplastic Small Round Cell Tumor
1
Colonic Neoplasms
1
Advanced Solid Tumors
1
Interventions
Granulocyte Colony-Stimulating Factor
5
Filgrastim
5
Thiotepa
3
Cyclophosphamide
3
sargramostim
2
Topotecan
2
Melphalan
2
Ifosfamide
2
Etoposide
2
Carboplatin
2
Busulfan
2
racotumomab
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
omburtamab I-131
1
entinostat
1
cixutumumab
1
atezolizumab
1
alvocidib
1
Thrombopoietin
1
Thalidomide
1
Stem Cell Transplantation
1
Sirolimus
1
Simvastatin
1
Radiotherapy, Intensity-Modulated
1
Platinum
1
Peripheral Blood Stem Cell Transplantation
1
Nivolumab
1
Mesna
1
Itraconazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Wilms Tumor
×
Platinum
×
Other solid neoplasm
×
Clear all
NCT05765084
2024-05-16
Immuno-MESODEC
University Hospital, Antwerp
Phase 1/2
Recruiting
15 enrolled